California Oncology of the Central Valley

Fresno, California 93710

0 studies enrolling now · 13 studies all time

What they study most

Breast Cancer, Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Hodgkin's Disease, Lymphoma, Large-Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasm Metastasis, Ovarian Cancer, Ovarian Neoplasms, Primary Peritoneal Carcinoma

Studies at this site

• Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. — Completed
• Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer — Stopped early
• An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry) — Completed
• Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer — Completed
• Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer — Stopped early
• A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease — Completed
• Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer — Stopped early
• Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels — Completed
• TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer — Completed
• TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer — Completed
• A Multiple Myeloma Trial in Patients With Bone Metastases — Completed
• MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma — Withdrawn before enrolling
• Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments — Completed